DENTSPLY SIRONA (DY2) Price & Analysis
DY2 Stock Chart & Stats
- Day’s Range
- EUR 8.40 - EUR 8.43
- 52-Week Range
- EUR 7.30 - EUR 12.53
- Previous Close
- EUR 8.28
- Volume
- 214
- Average Volume (3M)
- 206
- Market Cap
- EUR 1.70B
- Enterprise Value
- EUR 4.20B
- Total Cash (Recent Filing)
- EUR 239.00M
- Total Debt (Recent Filing)
- EUR 2.31B
- Price to Earnings (P/E)
- ―
- Beta
- 0.69
- Next Earnings
- Nov 05, 2026
- EPS Estimate
- 0.28
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 6.39%
Bulls Say, Bears Say
Bulls Say
Cash Generation
Positive operating and free cash flow provide internal funding for operations and selected investments despite reported losses. This resilience can support liquidity over the next several quarters, although the lower free cash flow versus earlier periods means cash generation has not fully resolved the broader earnings pressure.
Product Portfolio Breadth
A broad professional dental portfolio supports multiple stages of the clinical workflow and serves dentists, specialists and laboratories globally. This diversification gives DENTSPLY SIRONA several avenues for customer engagement and product adoption rather than relying on one technology or product category.
Wellspect Growth
Wellspect's growth demonstrates that new product launches and geographic expansion can generate momentum within the portfolio even while other segments face pressure. Continued adoption of recent products may provide a durable source of mix improvement and help support the company's return-to-growth plan.
Bears Say
Revenue And Profitability Pressure
Multi-year revenue contraction combined with a deeply negative TTM net margin indicates that the business has not yet restored sustainable earnings power. Persistent losses reduce reinvestment flexibility and make future improvement dependent on successful recovery in demand, execution and operating costs.
Elevated Leverage
The heavier debt burden and negative returns on equity reduce financial flexibility while operating performance remains weak. Higher leverage can constrain capital allocation and increase sensitivity to earnings shortfalls, making balance-sheet repair an important condition for a more durable turnaround.
Credit Covenant Pressure
Amending credit agreements to preserve covenant compliance signals that lenders are applying closer scrutiny while leverage remains elevated. Temporary restrictions on liens, subsidiary debt and restricted payments could limit financial flexibility and constrain management's options until compliance improves.
DENTSPLY SIRONA News
DY2 FAQ
What was DENTSPLY SIRONA’s price range in the past 12 months?
What is DENTSPLY SIRONA’s market cap?
When is DENTSPLY SIRONA’s upcoming earnings report date?
How were DENTSPLY SIRONA’s earnings last quarter?
Is DENTSPLY SIRONA overvalued?
Does DENTSPLY SIRONA pay dividends?
What is DENTSPLY SIRONA’s EPS estimate?
How many shares outstanding does DENTSPLY SIRONA have?
What happened to DENTSPLY SIRONA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of DENTSPLY SIRONA?
What is the TipRanks Smart Score and how is it calculated?
DENTSPLY SIRONA Stock Smart Score
Company Description
DENTSPLY SIRONA
DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Daniel T. Scavilla
- Employees
- 14,000
- Website
- www.dentsplysirona.com
- Address
- 13320 Ballantyne Corporate Place, Charlotte, NC, 28277-3607, US
DENTSPLY SIRONA (DY2) Earnings & Revenues
DY2 Company Deck
DY2 Earnings Call
Earnings Call SentimentNeutral
The call reflected a mixed but constructive tone: management reported near-term top-line pressures across multiple segments (notably OIS and consumables distributor headwinds in EMEA) and acknowledged tariff and geopolitical uncertainties. Offsetting these challenges were stable adjusted EBITDA and EPS, a one-time $44 million tariff refund that materially improved cash flow and EPS, continued strategic investments in sales, clinical education and R&D, expansion of dealer partnerships, and strong Wellspect performance. Management maintained full-year guidance and emphasized that improvements from the return-to-growth action plan should become more visible in Q4 and into 2027. Given balanced operational progress and strategic momentum against ongoing revenue and regional demand headwinds, the overall message is cautiously optimistic but still in turnaround mode.
View all DE:DY2 earnings summariesDY2 Net sales Breakdown
- 15.71% Equipment & Instruments
- 12.45% CAD/CAM
- 39.92% Essential Dental Solutions
- 6.17% Orthodontics
- 16.93% Implants & Prosthetics
- 8.83% Wellspect Healthcare
DY2 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 10 | 3 | 8 |
| Technical Analysis | 2 | 3 | 4 |
| Moving Averages | 8 | 0 | 4 |